Fig. 3
a Estimated overall survival in patients with MTV above the cohort’s median (42.8 ± 3.3 months) compared to patients with MTV below the cohort’s median (51.2 ± 2.7 months, p <  0.001), (b) in patients with TLG above the cohort’s median (37.1 ± 3.2 months) compared to patients with TLG below the cohort’s median (55.9 ± 2.5 months, p <  0.001) and (c) in patients with SUVpeak above the cohort’s median (39.9 ± 3.2 months) compared to patients with SUVpeak below the cohort’s median (54.1 ± 2.7 months, p <  0.001)